Mucosal prior to systemic application of recombinant adenovirus boosting is more immunogenic than systemic application twice but confers similar protection against SIV-challenge in DNA vaccine-primed macaques.
We investigated the immunogenicity and efficacy of a bimodal prime/boost vaccine regimen given by various routes in the Simian immunodeficiency virus (SIV) rhesus monkey model for AIDS. Twelve animals were immunized with SIV DNA-vectors followed by the application of a recombinant adenovirus (rAd5) expressing the same genes either intramuscularly (i.m.) or by oropharyngeal spray. The second rAd5-application was given i.m. All vaccinees plus six controls were challenged orally with SIVmac239 12 weeks post-final immunization. Both immunization strategies induced strong SIV Gag-specific IFN-gamma and T-cell proliferation responses and mediated a conservation of CD4(+) memory T-cells and a reduction of viral load during peak viremia following infection. Interestingly, the mucosal group was superior to the systemic group regarding breadth and strength of SIV-specific T-cell responses and exhibited lower vector specific immune responses. Therefore, our data warrant the inclusion of mucosal vector application in a vaccination regimen which makes it less invasive and easier to apply.
Schulte
Reiner
R
Working group Infection Models, German Primate Center, Kellnerweg, Goettingen, Germany.
Suh
You-Suk
YS
Sauermann
Ulrike
U
Ochieng
Washingtone
W
Sopper
Sieghart
S
Kim
Kwang S
KS
Ahn
So-Shin
SS
Park
Ki S
KS
Stolte-Leeb
Nicole
N
Hunsmann
Gerhard
G
Sung
Young C
YC
Stahl-Hennig
Christiane
C
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D049109:Cell Proliferation; D007114:Immunization / Q000379:methods*; D007117:Immunization, Secondary / Q000379:methods*; D007156:Immunologic Memory; D007273:Injections, Intramuscular; D007371:Interferon-gamma / Q000378:metabolism; D008253:Macaca mulatta; D009960:Oropharynx / Q000276:immunology; D018449:SAIDS Vaccines / Q000008:administration & dosage / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology; D019562:Viral Load; D014766:Viremia / Q000517:prevention & control
D018449:SAIDS Vaccines; D019444:Vaccines, DNA; D007371:Interferon-gamma